問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of Psychiatry

Division of Ophthalmology

Division of Neurology

Division of Nuclear Medicine

Division of General Internal Medicine

更新時間：2023-09-19

李正達Li, Cheng-Ta
  • Principal Investigator
  • Clinical Trial Experience (year) 22 years 10 個月

  • on5083@msn.com

Recruiting Trial

10Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

李正達

List

29Cases

2022-01-01 - 2024-04-09

Phase II

A Phase II Tolerability and Efficacy Study of PDC-1421 Treatment in Adult Patients with Attention-Deficit Hyperactivity Disorder (ADHD), Part II

  • Condition/Disease

    Attention-Deficit Hyperactivity Disorder (ADHD)

  • Test Drug

    PDC-1421 Capsule

Participate Sites
5Sites

Recruiting5Sites

2012-11-01 - 2013-05-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2014-10-09 - 2018-12-31

Phase III

Confirmatory Study of DSP-5423P in Patients with Schizophrenia <Phase 3>

  • Condition/Disease

    Schizophrenia

  • Test Drug

    DSP-5423P

Participate Sites
6Sites

Terminated6Sites

黃宗正
National Taiwan University Hospital

2013-12-01 - 2016-09-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2014-06-01 - 2018-09-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2012-05-01 - 2014-12-31

Phase II/III

  • Condition/Disease

  • Test Drug

Participate Sites
14Sites

Terminated14Sites

2012-05-01 - 2013-12-31

Phase II/III

  • Condition/Disease

  • Test Drug

Participate Sites
14Sites

Terminated14Sites

2019-09-01 - 2022-09-22

Phase III

A double-blind, placebo-controlled,randomized withdrawal, multicenter clinical trial evaluating the efficacy, safety, and tolerability of cariprazine in a dose-reduction paradigm in the prevention of relapse in bipolar I disorder patients whose current episode is manic or depressive, with or without mixed features

  • Condition/Disease

    Bipolar I disorder

  • Test Drug

    Cariprazine

Participate Sites
5Sites

Not yet recruiting1Sites

Recruiting4Sites

2019-10-01 - 2021-01-26

Phase III

A double-blind, placebo-controlled, randomized withdrawal, multicenter clinical trial evaluating the efficacy, safety, and tolerability of cariprazine in a dose-reduction paradigm in the prevention of relapse in patients with schizophrenia.

  • Condition/Disease

    Schizophrenia

  • Test Drug

    Cariprazine

Participate Sites
3Sites

Not yet recruiting2Sites

Study ended1Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB